Videos

Patients with blood cancers are at a much higher risk of complications if they contract COVID-19, says an expert from the Leukemia & Lymphoma Society (LLS).

Dr. Elie Fahed explains Beth’s diagnosis of triple-class refractory multiple myeloma and targeted therapy, and Beth recalls symptoms and side effects she experienced.

Mark provides insight into multiple myeloma from the perspective of the caregiver and offers advice to others who might be in the same position.

In an interview with CURE®, Ireland shared details on how to get involved in the "43 challenge" and offered some advice to families who may find themselves impacted by pediatric cancer.

Elie Fahed, MD, and Beth have an in-depth discussion on the physical and mental side effects Beth experiences while being treated for multiple myeloma.

Beth discusses the impact on quality of life caused by her second relapse of multiple myeloma, as well as shares her experience with subsequent treatment.

Beth compares her experiences with two multiple myeloma chemotherapy regimens, and Mark shares thoughts on Beth’s remission.

Beth describes the first relapse of multiple myeloma she experienced, and Elie Fahed, MD, explains what free light chains are and the role that they play.

Beth provides insight into her mindset at initial multiple myeloma diagnosis, after autologous stem cell transplant, while in remission, and at first relapse.

Elie Fahed, MD, describes the process and rationale for autologous stem cell transplant in multiple myeloma, and Beth shares her experience with receiving one.

Beth goes into the challenges she faced regarding multiple myeloma diagnosis due to her atypical case and discusses the first treatments that she received.

Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.

On behalf of the National Ovarian Cancer Coalition, CURE spoke with Dr. Debra Richardson, from Stevenson Cancer Center, about the basics of ovarian cancer and its treatments, clinical trials and psychosocial effects.

View the full CURE® Educated Patient® Webinar: Stomach Cancer 101 Series: Part I - Diagnosis and Staging on demand.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center discusses how she changed her perspective on finding a cure for myeloma and what her goals are when it comes to treating her patients.

CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

The term “survivor” is often used to describe people who have successfully completed their cancer treatments, but Sonia Su feels like it doesn’t quite capture the complexity of what it means to be in remission.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, and Sara A. Hurvitz, M.D., discuss treatment approaches and modifications during the COVID-19 pandemic.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.

Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.